ストックスクリーナーアプリを入手
13.32
2.15%
0.315
Atrium Therapeutics Inc (RNA) 最新ニュース
RNA News | ATRIUM THERAPEUTICS INC (NASDAQ:RNA) - ChartMill
Atrium Therapeutics, Inc.(NasdaqGS:RNA) added to Russell Microcap Value Benchmark Index - marketscreener.com
Atrium Therapeutics, Inc. (RNA) Stock Analysis: A Biotech Company Poised for Nearly 90% Upside - DirectorsTalk Interviews
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to Russell 3000E Growth Benchmark - marketscreener.com
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to Russell Microcap Index - marketscreener.com
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to Russell 3000E Index - marketscreener.com
RNA Forecast — Price Target — Prediction for 2027 - TradingView
Atrium Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNA) - TradingView
RNA Technical Analysis & Stock Price Forecast - Intellectia AI
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Arbiter Partners Capital Management LLC's Atrium Therapeutics Inc(RNA) Holding History - GuruFocus
Cantor Fitzgerald Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - Moomoo
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beat Amid Pre-Revenue Stage; Stock Inches HigherOperating Margin Analysis - Město Břeclav
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Unveiling a 111.86% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Pipeline Progress - newsline.com
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beats Estimates Despite Pre-Revenue Status; Stock Drops on Cash Burn ConcernsEPS Miss Report - newsline.com
Atrium Therapeutics (RNA) Slips 2.28% as Biotech Sector Faces HeadwindsPCR Moving Average - newsline.com
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beat Amidst Clinical Progress and Cost DisciplinePeak Earnings Alert - newsline.com
Atrium Therapeutics, Inc. (RNA) - DirectorsTalk Interviews
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineBuyback Announcement Report - newsline.com
RNAAtrium Therapeutics Inc Forecast, Target Price - Finviz
RNA Price Today: Atrium Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower Loss Drives EPS Beat, but Stock SlipsReturn On Capital - dars.gov.et
Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation - Yahoo Finance
Atrium Therapeutics Inc. (RNA) Holds Steady Near Resistance as Momentum BuildsCash Flow Strong Stocks - newsline.com
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring a 90.99% Potential Upside in RNA Therapeutics - DirectorsTalk Interviews
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Investor Sentiment - Newser
Atrium Therapeutics (RNA) Stages a Recovery: Testing Key Resistance at $13.69Crowd Stock Picks - Newser
Atrium Therapeutics Inc - Reuters
RNA Initiated Coverage by Leerink Partners -- Rating Set to Outp - GuruFocus
RA Capital (RNA) healthcare fund discloses 864,102 shares, 5.6% stake - Stock Titan
Leerink initiates Atrium Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Leerink Partners Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - Moomoo
Leerink Partners Initiates Coverage on Atrium Therapeutics With Outperform Rating, $25 PT - Moomoo
Atrium Therapeutics 1Q Loss/Shr 97c >RNA - Moomoo
Atrium Therapeutics Reports First Quarter 2026 Financial Results - Investing News Network
Atrium Therapeutics 1Q Rev $19.6M >RNA - Moomoo
Atrium Therapeutics Believes Cash Resources Sufficient to Fund Planned Ops Through Key Clinical Proof-Of-Concept Milestones >RNA - Moomoo
Atrium Therapeutics (RNA) Q1 2026: milestone revenue, higher R&D and $267.8M cash - Stock Titan
Atrium Therapeutics Reports Q1 2026 Financial Results and Corporate Progress - Intellectia AI
Atrium Therapeutics reports Q1 2026: $19.6M collaboration revenue, $267.8M cash - TradingView
Atrium Therapeutics, Inc. 1Q 2026: Revenue $19.6M, EPS $(0.97) — 10-Q Summary - TradingView
Atrium Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Atrium Therapeutics Q1 collaboration revenue surges after spin-off - TradingView
Atrium Therapeutics (Nasdaq: RNA) Q1 2026 results show higher revenue and loss - Stock Titan
Fierce Biotech Fundraising Tracker '26: Create corrals $122M; Isomorphic's $2B series B - Fierce Biotech
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring the 91% Potential Upside in RNA Therapeutics - DirectorsTalk Interviews
RNA (Atrium Therapeutics) revenue surges 70.8% in Q1, but shares slip as losses persist.Investment Community Signals - newser.com
How Atrium Therapeutics (RNA) performance compares to expectations (Underperforming) 2026-05-08Earnings Miss Risk - Newser
What Atrium Therapeutics (RNA) is doing to earn customer loyalty (Nudges Up) 2026-05-06Index Investing - newser.com
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring an 86% Potential Upside in RNA Therapeutics - DirectorsTalk Interviews
RNA 260618 33.00P (RNA260618P33000) Stock Options Chain | Quotes & News - Moomoo
0.86%
3.14%
大文字化:
|
ボリューム (24 時間):